Synergistic antitumor effect of chemotherapy and antisense-mediated ablation of the cell cycle inhibitor p27(KIP-1)

Clinical Cancer Research

Volumn 6, Issue 8, 2000, Pages 3006-3014

  Achenbach, Tatjana V ^a   Müller, Rolf ^a   Slater, Emily P ^a  

^a PHILIPPS UNIVERSITY MARBURG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ANTISENSE OLIGODEOXYNUCLEOTIDE; CYCLIN DEPENDENT KINASE INHIBITOR; FLAVOPIRIDOL; PHOSPHOROTHIOIC ACID DERIVATIVE; PROTEIN P27;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER CHEMOTHERAPY; CANCER INHIBITION; CELL CYCLE G2 PHASE; CELL CYCLE S PHASE; CONTROLLED STUDY; DRUG POTENTIATION; GENE EXPRESSION; HUMAN; HUMAN CELL; MALE; METAPHASE; MOUSE; NONHUMAN; PRIORITY JOURNAL;

ADENOCARCINOMA; ANIMALS; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CELL CYCLE; CELL CYCLE PROTEINS; CYCLIN-DEPENDENT KINASE INHIBITOR P27; CYCLIN-DEPENDENT KINASES; DRUG SYNERGISM; FLAVONOIDS; HELA CELLS; HUMANS; LUNG NEOPLASMS; MALE; MICE; MICE, NUDE; MICROTUBULE-ASSOCIATED PROTEINS; MITOSIS; OLIGONUCLEOTIDES, ANTISENSE; PIPERIDINES; PROSTATIC NEOPLASMS; THIONUCLEOTIDES; TRANSFECTION; TUMOR SUPPRESSOR PROTEINS; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 0342646964     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (38)

1. Drewinko, B., Patchen, M., Yang, L-Y., and Barlogie, B. Differential killing efficacy of twenty antitumor drugs on proliferating and nonproliferating human tumor cells. Cancer Res., 41: 2328-2333, 1981.
2. 1-phase progression. Genes Dev., 13: 1501-1512, 1999.
3. Johnson, D. G., and Walker, C. L. Cyclins and cell cycle checkpoints. Annu. Rev. Pharmacol. Toxicol., 39; 295-312, 1999.
4. Soos, T. J., Park, M., Kiyokawa, H., and Koff, A. Regulation of the cell cycle by CDK inhibitors. Results Probl. Cell Differ., 22: 111-131, 1998.
5. Roussel, M. F. The INK4 family of cell cycle inhibitors in cancer. Oncogene. 18: 5311-5317, 1999.
6. Huschtscha, L. I., and Reddel, R. R. p16(INK4a) and the control of cellular proliferative life span. Carcinogenesis (Lond.), 20: 921-926, 1999.
7. Kip1, a cyclin-dependent kinase inhibitor and a potential mediator of extracellular antimitogenic signals. Cell, 78: 59-66, 1994.
8. Polyak, K., Kato, J. Y., Solomon, M. J., Sherr, C. J., Massague, J., Roberts, J. M., and Koff, A. p27Kip1, a cyclin-Cdk inhibitor, links transforming growth factor-β and contact inhibition to cell cycle arrest. Genes Dev., 8: 9-22, 1994.
9. Reynisdottir, I., Polyak, K., lavarone, A., and Massague. J. Kip/Cip and Ink4 Cdk inhibitors cooperate to induce cell cycle arrest in response to TGF-β. Genes Dev., 9: 1831-1845, 1995.
10. Hannon, G. J., and Beach, D. p15INK4B is a potential effector of TGF-β-induced cell cycle arrest. Nature (Lond.), 371: 257-261, 1994.
11. Coats, S., Flanagan, W. M., Nourse, J., and Roberts, J. M. Requirement of p27Kip1 for restriction point control of the fibroblast cell cycle. Science (Washington DC), 272: 877-880, 1996.
12. 0 state) in fibroblasts. J. Biol. Chem., 271: 18337-18341, 1996.
13. Ladha, M. H., Lee, K. Y., Upton, T. M., Reed, M. F., and Ewen, M. E. Regulation of exit from quiescence by p27 and cyclin D1-CDK4. Mol. Cell. Biol., 18: 6605-6615, 1998.
14. Dao, M. A., Taylor, N., and Nolta, J. A. Reduction in levels of the cyclin-dependent kinase inhibitor p27(kip-1) coupled with transforming growth factor β neutralization induces cell-cycle entry and increases retroviral transduction of primitive human hematopoietic cells. Proc. Natl. Acad. Sci. USA, 95: 13006-13011, 1998.
15. Ashton, A. W., Watanabe, G., Albanese, C., Harrington, E. O., Ware, J. A., and Pestell, R. G. Protein kinase C δ inhibition of S-phase transition in capillary endothelial cells involves the cyclin-dependent kinase inhibitor p27(Kipl). J. Biol. Chem., 274: 20805-20811, 1999.
16. Rivard, N., Boucher, M. J., Asselin, C., and L'Allemain, G. MAP kinase cascade is required for p27 down-regulation and S phase entry in fibroblasts and epithelial cells. Am. J. Physiol., 277: C652-C654, 1999.
17. Kiyokawa, H., Kineman, R. D., Manova-Todorova, K. O., Soares, V. C., Hoffman, E. S., Ono, M., Khanam, D., Hayday, A. C., Frohman, L. A., and Koff, A. Enhanced growth of mice lacking the cyclin-dependent kinase inhibitor function of p27(Kipl). Cell, 85: 721-732, 1996.
18. Fero, M. L., Rivkin, M., Tasch, M., Porter, P., Carow, C. E., Firpo, E., Polyak, K., Tsai, L. H., Broudy, V., Perlmutter, R. M., Kaushansky, K., and Roberts, J. M. A syndrome of multiorgan hyperplasia with features of gigantism, tumorigenesis, and female sterility in p27(Kip1)-deficient mice. Cell, 85: 733-744, 1996.
19. Kiyokawa, H., and Koff, A. Roles of cyclin-dependent kinase inhibitors: lessons from knockout mice. Curr. Top. Microbiol. Immunol., 227: 105-120, 1998.
20. St. Croix, B., Florenes, V. A., Rak, J. W., Flanagan, M., Bhattacharya, N., Slingerland, J. M., and Kerbel, R. S. Impact of the cyclin-dependent kinase inhibitor p27kip1 on resistance of tumor cells to anticancer agents. Nat. Med., 2: 1204-1210, 1996.
21. Wickstrom, E. Clinical Trials of Genetic Therapy with Antisense DNA and DNA Vectors. New York: Marcel Dekker, Inc., 1998.
22. Sausville, E. A., Zaharevitz, D., Gussio, R., Meijer, L., Louarn-Leost, M., Kunick, C., Schultz, R., Lahusen, T., Headlee, D., Stinson, S., Arbuck, S. G., and Senderowicz, A. Cyclin-dependent kinases: initial approaches to exploit a novel therapeutic target. Pharmacol. Ther., 82: 285-292, 1999.
23. Gray, N., Detivaud, L., Doerig, C., and Meijer, L. ATP-site directed inhibitors of cyclin-dependent kinases. Curr. Med. Chem., 6: 859-875, 1999.
24. Pietenpol, J. A., Bohlander, S. K., Sato, Y., Papadopoulos. N., Liu, B., Friedman, C., Trask, B. J., Roberts, J. M., Kinzler, K. W., Rowley, J. D., and Vogelstein, B. Assignment of the human p27/Kip1 gene to 12p13 and its analysis in leukemias. Cancer Res., 55: 1206-1210, 1995.
25. Arguello, F., Alexander, M., Sterry, J. A., Tudor, G., Smith, E. M., Kalavar, N. T., Greene, J. F., Koss, W., Morgan, C. D., Stinson, S. F., Siford, T. J., Alvord, W. G., Klabansky, R. L., and Sausville, E. A. Flavopiridol induces apoptosis of normal lymphoid cells, causes immunosuppression, and has potent antitumor activity in vivo against human leukemia and lymphoma xenografts. Blood, 91: 2482-2490, 1998.
26. Lau, Q. C., Brüsselbach, S., and Müller, R. Abrogation of c-Raf expression induces apoptosis in tumor cells. Oncogene, 16: 1899-1902, 1998.
27. Jérome, V., and Müller, R. Tissue-specific, cell cycle-regulated chimeric transcription factors for the targeting of gene expression to tumor cells. Hum. Gene Ther., 9: 2653-2659, 1998.
28. Teicher, B. A. Cancer Therapeutics: Experimental and Clinical Agents. Totowa, NJ: Humana Press, 1997.
29. Steeg, P. S., and Abrams, J. S. Cancer prognostics: past, present and p27. Nat. Med., 3: 152-154, 1997.
30. Bible, K. C., and Kaufmann, S. H. Flavopiridol: a cytotoxic flavone that induces cell death in noncycling A549 human lung carcinoma cells. Cancer Res., 56: 4856-4861, 1996.
31. Brüsselbach, S., Nettelbeck, D. M., Sedlacek, H-H., and Müller, R. Cell cycle-independent induction of apoptosis by the anti-tumor drug Flavopiridol in endothelial cells. Int. J. Cancer, 77: 146-152, 1998.
32. Lowenheim, H., Furness, D. N., Kil, J., Zinn, C., Gultig, K., Fero, M. L., Frost, D., Gummer, A. W., Roberts, J. M., Rubel, E. W., Hackney, C. M., and Zenner, H. P. Gene disruption of p27(Kip1) allows cell proliferation in the postnatal and adult organ of corti. Proc. Natl. Acad. Sci. USA, 96: 4084-4088, 1999.
33. Franklin, D. S., Godfrey, V. L., Lee, H., Kovalev, G. I., Schoonhoven, R., Chen-Kiang, S., Su, L., and Xiong, Y. CDK inhibitors p18(INK4c) and p27(Kip1) mediate two separate pathways to collaboratively suppress pituitary tumorigenesis. Genes Dev., 12: 2899-2911, 1998.
34. Zindy, F., Cunningham, J. J., Sherr, C. J., Jogal, S., Smeyne, R. J., and Roussel, M. F. Postnatal neuronal proliferation in mice lacking Ink4d and Kip1 inhibitors of cyclin-dependent kinases. Proc. Natl. Acad. Sci. USA, 96: 13462-13467, 1999.
35. Park, M. S., Rosai, J., Nguyen, H. T., Capodieci, P., Cordon-Cardo, C., and Koff, A. p27, and Rb are on overlapping pathways suppressing tumorigenesis in mice. Proc. Natl. Acad. Sci. USA, 96: 6382-6387, 1999.
36. Coats, S., Whyte, P., Fero, M. L., Lacy, S., Chung, G., Randel, E., Firpo, E., and Roberts, J. M. A new pathway for mitogen-dependent cdk2 regulation uncovered in p27(Kip1)-deficient cells. Curr. Biol., 9: 163-173, 1999.
37. Cheng, M., Olivier, P., Diehl, J. A., Fero, M., Roussel, M. F., Roberts, J. M., and Sherr, C. J. The p21(Cip1) and p27(Kip1) CDK "inhibitors" are essential activators of cyclin D-dependent kinases in murine fibroblasts. EMBO J., 18: 1571-1583, 1999.
38. Sgambato, A., Cittadini, A., Faraglia, B., and Weinstein, I. B. Multiple functions of p27(Kip1) and its alterations in tumor cells: a review. J. Cell Physiol., 183: 18-27, 2000.